Filgrastim skal seponeres, hvis der opstår myelodysplastisk syndrom eller leukæmi.
If patients with SCN develop abnormal cytogenetics, the risks and benefits of continuing filgrastim should be carefully weighed; Filgrastim should be discontinued if MDS or leukaemia occurs.